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Introduction1 
Squamous Cell Carcinoma (SCC) is the most frequently diagnosed oral cancer. It is important 
to note that while this term is oftentimes used to include both oral cavity and oropharyngeal 
SCC tumors, these are both separate entities [1, 2]. Both are included within the larger group 
of Head and Neck Squamous Carcinoma (HNSCC), which is the sixth most common form of 
cancer worldwide [3]. Herein, the term oral SCC (OSCC) is used in reference to both SCC of 
the oral cavity and oropharynx. OSCC represents ~2-3% of all human cancers [4]. In 2012, 
more than 300 000 and 140 000 new cases of lip/oral cavity-SCC and oropharyngeal SCC 
were diagnosed worldwide [2]. In Western Countries, the most frequent primary sites of oral 
cavity SCC are the tongue and the floor of the mouth [2].  
The major risk factors of OSCC include tobacco and alcohol consumption [2, 5]. Human 
papillomavirus (HPV) is emerging as an additional important risk factor, particularly 
associated with oropharyngeal SCC [2]. Oral cancerogenesis is a multistep process, in which 
multiple genetic and cellular alterations are involved [5]. In the oral cavity, the most common 
potentially malignant disorder is Oral leukoplakia [6, 7]. Imbalance of growth factors such as 
EGF, VEGF, PDGF, and TGF-β1, caused by gene mutations associated with tobacco use 
and/or HPV 16 and 18 infection, may also contribute [2, 8–12].  
Regional lymphatic metastasis and distant metastasis (DM) occurs especially in advanced 
stages of OSCC and correlates with a poor prognosis [8, 13, 14]. Indeed, the 5-year survival 
rate of OSCC in the US is 63%. The survival rate has been reported to be less in the 
presence of lung and bone metastases [2, 14]. DM was reported in 6.6% of upper gingiva and 
4.1% of tongue carcinomas [15]. However, another study reported that the majority of patients 
with neck lymph node metastasis had tongue cancer (69.6%) [13]. In a larger study consisting 
of 502 patients affected by oral cavity SCC, only 54 patients (10.8%) presented DMs, 
especially in lung, bone, and the mediastinum [14]. 
Treatment of OSCC is stage-dependent. Early stages treatments involve surgery or 
radiotherapy (RT) alone. Advanced stages require surgery and/or RT + chemotherapy (CT) 
as adjuvant treatment [2, 4, 10]. Indeed, the addition of CT significantly improved overall 
survival (OS) [1]. In contrast, OS was not improved in oral cavity SCC patients undergoing 
induction CT. However, it may result in a reduction of loco-regional recurrence [16]. The most 
commonly used chemotherapeutic agents are cisplatin (CDDP) and fluorouracil (5-FU), while 
other drugs such as carboplatin, paclitaxel, docetaxel (DTX), and methotrexate (MTX) have 
been reported [1,12,17] Molecular-targeted agents (e.g. cetuximab and bevacizumab),  gene 
therapies, photodynamic therapy (PDT), and immunotherapy have also been explored 
[3,18,19]. Indeed, CT results in several adverse side effects and in multi-drug resistance 
(MDR), which leads to a poor therapeutic response in several cases [4, 19–22]. Adverse 
effects of CT stem from non-specific distribution of chemotherapeutics and vary from patient 
to patient and type of treatment (e.g. agent, duration, dosage) [1, 20, 23]. For instance, 
important adverse effects of CDDP include nephrotoxicity, neurotoxicity, and gastrointestinal 
toxicity [23]. Also MDR contributes to CT toxicity, due to exposure of healthy cells to high 
levels of expelled drug [19, 20]. The MDR mechanisms in oral cancer are still under 
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investigation and contribute to failure of treatment in advanced stages of OSCC [19]. The 
principal mechanism consists in over-expression of multi-drug transporters, which are 
responsible for drug efflux from tumor cells, decreasing their efficacy [19, 20]. Indeed, studies 
have reported an enhanced expression of P-gp, MDR1 and ABCG2 in cell lines resistant to 
CDDP, 5-FU, and in recurrent OSCC [19, 22]. 
To overcome the limitations of CT, nanotechnology-based systems are emerging in cancer 
therapy [17, 20]. In the past decades, the intersection of nanotechnology with medicine, 
physics, mathematics and biology has given rise to the new field of nanomedicine. 
Nanoparticle (NP) systems have demonstrated high drug carrier capabilities and site-specific 
drug accumulation in tumors [20, 24, 25]. Several preclinical studies involving NP-based CT 
delivery reported higher drug solubility, drug circulation times, and efficacy when compared to 
conventional free drug formulations [20, 24, 26]. NPs have been reported as suitable carriers 
of chemopreventive compounds, nucleic acids, and diagnostic agents for both diagnostic and 
therapeutic (i.e. theranostic) purposes [7, 27–30]. In light of the many advantages afforded by 
NPs, several NP systems, such as Doxil/Caelix® and Abraxane®, have been clinically 
approved for the treatment of certain types of cancer, such as ovarian cancer and metastatic 
breast cancer. Several other systems, such as gold nanoshells, are currently undergoing 
clinical trials [31, 32]. However, to date, no NP-based treatment has been approved for 
HNSCC [31, 32]. Clinical trials have been performed and other trials are currently underway 
to treat advanced HNSCC [31, 33, 34]. As an example, a liposomal Dox (Doxil/Caelix®) was 
explored in certain instances of HNSCC [33, 35, 36].  
An additional advantage of nanomedicine platforms is their versatility, and the ability to 
rationally design NPs to overcome sequential biological barriers (e.g. sequestration by the 
mononuclear phagocytic system, MDR), which have been shown to limit the efficacy of NP-
based drug delivery [20, 24, 26, 31]. Indeed, the first NPs developed were able to accumulate 
in tumors passively through the enhanced permeability and retention effect (EPR, Fig 1) [37]. 
This is owed to the fact that tumor vasculature is characterized by the presence of larger 
endothelial fenestrations than normal endothelium, allowing for passive extravasation of NPs. 
However, the difference of EPR between different types of cancer may affect NP delivery to 
the tumor and consequently their efficacy [20, 37]. Enhanced tumor targeting was obtained in 
second-generation NPs with the addition of components for active targeting (e.g. monoclonal 
antibodies) and stimulus-responsive release (e.g. pH-or hypoxia sensitive) (Fig.1) [20, 24, 25, 
31, 32, 38, 39]. However, none of the NPs are capable of evading the multiple biological 
barriers to NP drug delivery, and none of these are FDA and/or EMA approved [20, 24, 26, 
31, 32]. Third-generation NPs (MSVs) consist of multistage nanovectors (MSVs). MSVs 
consist of first stage mesoporous silicon particles (S1MPs) and second stage-NPs embedded 
within nanopores (Fig. 1). Following IV administration, S1MPs are able to interact with the 
endothelium, allowing for release of second-stage NPs directly into the tumor interstitium [24, 
39, 40].  
The aim of the present review is to summarize the current preclinical research in the field of 
NP-based drug delivery for OSCC therapy. Future perspectives and therapeutic strategies are 
also suggested. 
 
OSCC nano-based chemoprevention  
Chemoprevention for OSCC includes drugs used to reverse, prevent or suppress malignant 
transformation of pre-neoplastic cells [7]. In this field, natural plant compounds such as 
flavonoids and stilbenes have received great attention, with the majority (e.g. curcumin, 
naringenin) reported to show promising anti-tumor activity in preclinical studies [5, 22, 41, 42]. 
However, bioactive plant compounds have poor bioavailability and poor solubility, which 
  
reduce their efficacy in clinical studies [5, 7, 41, 43]. To overcome this problem, NP-based 
chemoprevention has recently been explored preclinically [5, 7, 22, 41, 43]. 
 
Curcumin 
NPs loaded with curcumin (Cur), a phenolic compound, were used for OSCC therapy in 
several studies [22, 43, 44]. PLGA NPs were shown to exert a dose- and time-dependent 
reduction in viability of CAL27-CDDP-resistant tongue tumor cells (CAR cells) [22]. In 
contrast, no significant effect was observed in normal human oral keratinocytes and gingival 
fibroblasts. CAR cells treated with Cur-NPs resulted in an increase of apoptosis, due to an 
increase of ROS production and a downregulation of multiple drug resistance protein 1 
(MDR1) compared to untreated controls. Silica NPs loaded with Cur (Cur-SiNPs) had a higher 
cell uptake and toxicity in oral cavity SCC cells than a free Cur formulation [43]. Cur-SiNPs 
followed by exposure to light were also compared with a free Cur formulation followed by the 
same treatment [43]. Phototoxicity was significantly increased in cells treated with Cur-SiNPs 
compared to a free Cur formulation. Cur-SiNPs induced cell necrosis due to membrane 
damage, and showed a higher downregulation of NF-κB, VEGF, MMP-9, and TNF-α 
expression than a free Cur formulation. Lee et al. prepared Cur microemulsions and 
evaluated their cytotoxicity with and without low-frequency ultrasound on tongue cancer cells 
in comparison with a free Cur formulation [44]. Cur microemulsions were more cytotoxic than 
a free Cur formulation, and cell viability further decreased with the addition of ultrasound [44]. 
Mucoadhesive polycaprolactone (PCL) NPs loaded with Cur were also obtained by coating 
them with chitosan (CS) for local therapy of oral cavity SCC [34, 45].These Cur-NPs induced 
apoptotic death of tongue tumor cells and were less cytotoxic than a free Cur formulation [45]. 
 
Other plant compounds 
Naringenin is a flavonoid derived from grape fruits and cherries, with proven anti-cancer 
effects [41]. Sulfikkarali et al. [41] prepared Naringenin-loaded NPs (NARNPs) using 
Eudragit® E cationic copolymer to enhance drug solubility. The chemopreventive effect was 
evaluated in a DMBA-induced oral cavity SCC hamster model, which showed 
histopathological changes consistent with those seen in humans [46]. The oral cavity SCC 
group treated orally with NARNPs presented only mild dysplasia, compared to a free NAR 
formulation and controls. Moreover, NARNPs inhibited tumor proliferation and increased 
antioxidant levels compared to controls. 
Gavin et al. [47] developed mucoadhesive CS-layered nanoemulsions loaded with genistein 
(Gen) and processed them into buccal tablet formulations. Cytotoxicity assays on OSCC cell 
lines revealed significant efficacy of CS-layered Gen-nanoemulsions at early time points 
compared to aqueous Gen-nanoemulsions [47]. In a more recent study, Li et al. [5] evaluated 
the effect of salvianolic acid B (SalB) phospholipid complex-loaded NPs (SalB-PLC-NPs) on 
oral pre-cancerous and OSCC cell lines. SaIB is a bioactive component used as an active 
marker for Salvia miltiorrhiza Bge (Danshen) products by the National Pharmacopoeia 
Council of China. Indeed, the dried root of Salvia miltiorrhiza Bge (Danshen) has been used in 
traditional Chinese medicine against several diseases, including cancer [48]. Different 
concentrations of SalB-PLC-NPs significantly inhibited cell growth in both pre-cancerous and 
cancer cells compared to a free drug formulation of SalB [5].  
 
Nano-based chemotherapy   
CT can prove effective in advanced stage OSCC, but there is not evidence to support its 
benefits as an induction treatment [1, 4, 10, 16]. Moreover, drug-related adverse side effects 
and acquired MDR limit its efficacy. Therefore, several in vitro and in vivo studies reported the 
  
development of NPs loaded with chemotherapeutics such as CDDP, 5FU, and molecular-
targeted agents. 
 
5-FU 
Zhao et al. [49] synthesized 5FU-monomeric self-assembled nucleoside NPs (5-FU-SNNP) 
and evaluated their anti-tumor effect in vitro and in vivo. In the in vitro study, normal human 
oral cells were also used as controls. SNNPs exhibited low cytotoxicity for both oral cavity 
SCC and controls. Low toxicity of SNNPs was also reported in vivo. In a subcutaneous 
xenograft model of oral cavity SCC, 5-FU-SNNPs were locally injected for a duration of 3 
weeks. A long-term effect of 5-FU was observed in the NP formulation compared to a free 
drug formulation of 5-FU. Moreover, a significant reduction in tumor growth and toxicity were 
reported using 5-FU-SNNPs compared to a free drug formulation of 5-FU. Similar results 
were obtained with a systemic treatment of 5-FU-SNNPs. 
 
CDDP 
Ligand-decorated cancer-targeted CDDP-loaded PLGA-PEG/NR7 NPs were formulated by 
Wang et al. [23]. NR7 peptide is based on alignment of the tripeptide motif with the EGF 
binding domain. Targeted NPs presented a higher uptake by oral cavity SCC cells, 
cytotoxicity, and cell apoptosis than non-targeted NPs and CDDP. In contrast, polymeric 
micelles carrying CDDP (NC-6004) exhibited lower cytotoxicity of human oral cavity SCC cell 
lines compared to CDDP [50]. Lower renal injury was observed in subcutaneous xenograft 
models treated with NC-6004 than in those treated with CDDP. Interestingly, a sublingual 
injection of NC-6004 significantly decreased lymphatic metastasis rates compared to CDDP in 
an ortothopic xenograft model of metastatic oral cavity SCC [50]. 
 
Doxorubicin 
Doxorubicin (Dox) is a potent chemotherapeutic, whose cardiotoxicity limits clinical 
applications. Consequently, a liposomal form of Dox (Doxil®) was developed to counter the 
adverse effects of the drug, indeed resulting in lessened cardiotoxicity [33, 35]. Liposomal 
Dox was used in clinical studies as an adjuvant chemotherapy in HNSCC [33, 35, 36, 51]. 
These studies reported improved results in the treatment of primary tumors, but not 
metastases [33, 35, 36]. Other Dox-loaded NPs have been developed for OSCC therapy. 
Mohan et al. [52] prepared PEGylated and non-PEGylated liposomes loaded with Dox + 
resveratrol (Res), a plant stilbenoid. The drug combination was more effective in HNSCC cells 
compared to both free and liposomal forms of single drugs. Apoptosis and DNA damage was 
significantly increased in the dual-drug-loaded liposome group compared to other controls. 
Abbasi et al. [53–55] examined stimuli-responsive cationic mesoporous silica NPs loaded with 
MTX and Dox on a 4-NQO-induced oral cavity SCC rat model. Both free and nanoforms of 
Dox combined with MTX were orally or IV administrated for 14 weeks. IV administration of 
MTX-Dox NPs was more effective in reducing expression of MMPs and VEGF than the oral 
administration, while no difference was reported regarding HER2 expression. This correlated 
with a lower stage of oral cavity SCC in groups treated with NPs compared to those treated 
with Dox and controls [53–55].  
Saiyin et al. [56] loaded the autophagy inhibitor LY294002 in pH-responsive hyperbranched 
polyacylhydrazone (HPAH)-Dox nanomicelles. Initially, HPAH-Dox presented significantly 
higher cellular uptake than Dox. In subsequent experiments, addition of LY294002 to HPAH-
Dox (LY294002-HPAH-Dox) inhibited autophagy in CAL-27 cells. This resulted in a significant 
increase in chemosensitivity to Dox compared to HPAH-Dox + free drug formulation of 
LY294002 and HPAH-Dox. 
  
 
 
 
Magnetic NPs 
Due to their nano-size and the potential to modify their surface with antibodies, drugs, and 
MRI contrast agents, magnetic NPs have been used as theranostic agents [27–29, 34].  In 
addition, they are capable of converting non-ionizing electromagnetic radiation produced by 
an energy source (e.g. a laser) into heat energy, locally inducing apoptosis (i.e. the plasmon 
resonance phenomenon) [57]. Consequently, certain magnetic NPs (e.g. gold nanoshells) 
have been explored in clinical trials for photothermal ablation of several types of tumors, 
including HNSCC [31, 32, 34].  
 
Gold NPs 
Several types of gold NPs are emerging as promising drug carriers and photothermal agents 
[57].  Colloidal AuNPs are obtained from the reduction of Au, and respond to exposure of 
near-infrared (NIR) light by converting it into heat [34, 57–59]. The efficacy of AuNPs alone or 
in combination with laser was investigated in a DMBA-induced oral cavity SCC hamster 
model [58]. In this study, AuNPs were directly injected into the tumor or in buccal pouches 
(controls). A significantly higher decrease in tumor growth and PCNA expression was 
observed in the group treated with AuNPs + laser than those treated with laser and with 
AuNPs only.  
Iron-core NPs with a gold shell (Fe@Au) were designed more than a decade ago, to delay 
iron oxidation and improve its magnetic properties [29, 60]. OSCC toxicity of Fe@Au was due 
to mitochondria-mediated autophagy, while normal oral cells were not affected [60]. Wu et al. 
[29] demonstrated that Fe@Au pre-cancer- and cancer-specific toxicity in vitro and in vivo 
correlated with release of Fe3+ ions and diminished when exposed to air for 7 days.  
Gold nanoshells consisting of silica-core NPs coated with gold [34, 57, 59] were used in an 
unpublished clinical trial (NCT00848042) in combination with NIR photothermal therapy to 
treat refractory HNSCC.  
Melancon et al. [38] developed gold nanoshells with a superparamagnetic iron oxide silica 
core (SPIO@AuNPs) and conjugated them with cetuximab (C225 monoclonal antibody). In 
this study, EGFR negative and EGFR overexpressing OSCC cell lines were used. Initially, 
binding of C225-SPIO@AuNPs to cells overexpressing EGFR was significantly higher when 
compared to non-targeted NPs. In a second experiment, targeted and non-targeted NPs were 
combined with NIR laser to kill OSCC cells, with the lowest cell viability observed in the group 
receiving C225-SPIO@AuNPs plus laser treatment. 
 
Other types of magnetic NPs 
In a study by Hackenberg et al. [61], UVA-1-activated zinc-oxide (ZnO) NPs were used alone 
or in combination with paclitaxel/CDDP and UVA-1 irradiation in oral cavity SCC cell lines. 
UVA-1 and NPs alone did not induce any significant increase in apoptosis or necrosis, 
compared to UVA-1 + NPs. The IC50 of both CDDP and paclitaxel did not significantly 
change when combined with non-irradiated NPs. In contrast, cell viability significantly 
decreased when chemotherapeutic agents were combined with irradiated NPs. Effective 
photothermal therapy in vitro (CAL-27 cells) was also obtained through combination with 
newly-developed cupreous complex-loaded CS (CuCC) NPs [62]. NPs in combination with 
laser resulted in laser power-dependent apoptosis.  
In a more recent study, Lucky et al. [27] studied the biocompatibility, toxicity, and efficacy of 
PEGylated titanium dioxide (TiO2) NIR excitable up-conversion NPs (UCNs) targeted against 
  
EGFR in a subcutaneous xenograft model of tongue cancer. UCNs were developed to 
increase the penetration depth of conventional PDT [27]. Targeted UCNs demonstrated 
higher cell uptake in vitro, resulting in higher cell death when UCNs were irradiated compared 
to non-targeted UCNs. In vivo toxicity studies of targeted UCNs did not reveal significant 
hematological or organ alterations. Efficacy studies reported that UCNs + NIR laser caused 
the highest tumor growth inhibition compared to NPs and PDT alone. In addition, treatment 
with UCNs + NIR laser resulted in larger areas of tumor necrosis and higher down-regulation 
of Ki67 than untreated controls [27].  
 
Magnetic NPs for other applications 
Cancer stem cells (CSCs) have high self-renewal capabilities and have been suggested to 
contribute to OSCC recurrence, although their characterization is still under investigation. 
Breast CSCs were recently targeted by AuNPs containing Dox [63]. Satapathy et al. [63] 
modified silver-based NPs (AgNPs) adding Quinacrine (QC), a 9-amino acridine derivative 
with anticancer activities, followed by encapsulation in PLGA. Interestingly, hybrid QAgNPs 
had different features than Ag and QC NPs (NQCs). Hybrid NPs were tested in oral cavity 
SCC cells, other neoplastic cell lines, and oral cavity SCC spheroids. Treatment with hybrid 
NPs resulted in a significant increase of pro-apoptotic protein BAX, a decrease of anti-
apoptotic protein BCL-XL expression, and a blocking of cell cycle in S phase compared to 
AgNPs and NQCs. On spheroids, hybrid NPs also induced apoptosis in CSCs by damaging 
DNA and inhibiting DNA repair pathways (e.g. BER). Lastly, the angiogenesis inhibition 
capabilities of hybrid NPs was evaluated in vivo (Chick Chorioallantoic Membrane [CAM] 
Assay) and compared with NQCs and AgNPs. Hybrid NPS exerted the highest anti-
angiogenic activity [63].  
Sonodynamic therapy (SDT) consisted in replacement of light in PDT with ultrasound and is 
emerging as a possible treatment for oral cavity SCC [64]. Moosavi Nejad et al. [64] evaluated 
the effects of photocatalytic TiO2 NPs combined with high intensity focused ultrasound (HIFU) 
on oral cavity SCC cells and subcutaneous xenograft models. Cytotoxic effects were 
significantly higher in the HIFU + NPs group than HIFU or NPs alone. Upon morphological 
assessment, NPs significantly enhanced cell damage caused by HIFU compared to HIFU 
alone. In vivo, HIFU treatment with and without NPs resulted in large areas of tumor necrosis 
and hemorrhage. Interestingly, cell penetration of NPs in the HIFU groups was higher than 
that of NPs alone. 
 
Other nanotechnology-based-drug-delivery systems  
Hyper-branched polymers (HPEE) were described for the first time in PDT through the 
formulation of HPEE chlorine (e6) NPs [65]. The anti-proliferative effects of both HPEE-e6 
NPs and free e6 were evaluated in combination with PDT on CAL-27 cells. HPEE-e6 NPs 
were more effective at inhibiting cell survival than free e6. 
 
Nanotechnology-based gene therapy 
Lipid-based NPs have proven to be suitable non-viral delivery vectors for gene therapy, due 
to their lack of immunogenicity, high tumor-specificity, and safety [66]. As a result, their use 
has been reported in OSCC gene therapy [21, 67]. 
 
DNA transfection 
In a study by Yu et al., the anticancer effect of PEG-poly (g-benzyl-l-glutamate) (PBLG) NPs 
loaded with the herpes simplex virus thymidine kinase (HSV-TK) gene was evaluated in 
tongue cancer cells and on DMBA-induced oral cavity SCC [68]. The NPs exerted higher 
  
gene-transfer efficiency in vitro and DNA protection than Lipofectamine. However, their anti-
tumor effects in vitro and in vivo were not significantly different from those of Lipofectamine 
[68]. 
Magnetic NPs have also been used as vehicles for gene therapy, to improve targeting 
efficiency [30]. Miao et al. [30] prepared PEI-modified Fe3O4 magnetic NPs to deliver a human 
TNF-related apoptosis-inducing ligand (TRAIL) gene driven with an hTERT tumor-specific 
promoter (pACTERT-TRAIL). The experiment was performed on tongue tumor cells with a 
magnet placed under the plate. pACTERT-TRAIL NPs demonstrated a higher transfection 
efficiency and induction of apoptosis than conventional PEI/lipofectin. A similar efficiency of 
pACTERT-TRAIL NPs was reported in a subcutaneous xenograft tongue cancer model, 
resulting in higher tumor growth inhibition than controls. In addition, TRAIL and TUNEL-
positive tumor cells were observed in treated mice compared to controls, in which tumor cells 
were TUNEL-negative. 
 
siRNA transfection 
In two recent studies [21, 67], lipid-calcium-phosphate NPs (LCP-NPs) were used to deliver 
HIF1α [67] and VEGF-A siRNA [21], respectively, in combination with photosan-mediated 
PDT in tongue cancer cells. Photosan is a photosensitizer drug, which is locally administered 
to induce neoplastic cell death through ROS production after light exposure. However, 
multiple treatments are often necessary for larger lesions and PDT may enhance tumor VEGF 
and HIF1α (hypoxia gene) expression. In both studies, LCP-NPs were actively targeted to 
sigma receptors (σR), commonly overexpressed in HNSCC and other types of tumors [21, 
67]. σR-targeted-LCP NPs loaded with HIF1α siRNA demonstrated a higher tumor cell uptake 
than non-targeted NPs [67]. The combination of HIF1α siRNA LCP-NPs + PDT was more 
effective in reducing tumor growth than scrambled siRNA LCP + PDT in a subcutaneous 
xenograft tongue cancer model. Additionally, treatment with HIF1α siRNA LCP-NPs with and 
without PDT resulted in a reduction of tumor size, down-regulation of angiogenic and 
proliferative markers, and an up-regulation of apoptosis markers [67]. Lecaros et al. [21] 
obtained similar results in vivo with σR-targeted LCP-NPs loaded with VEGF-A siRNA with 
and without PDT. The group with VEGF-siRNA LCP-NPs + PDT presented a greater inhibition 
of tumor growth and angiogenesis than scrambled siRNA LCP-NPs + PDT. As expected, 
VEGF-A, α-SMA, ki67, and apoptosis markers were decreased and increased in treated 
groups compared to PBS controls and PDT + scrambled siRNA groups. 
 
Future perspectives and strategies 
Many of the studies included herein reported the use of single entity-particles with active 
targeting and/or stimulus-responsive components (i.e. second-generation NPs, Fig.1) for local 
or systemic OSCC therapy. These systems allowed for improved solubility, drug 
bioavailability, increases in anti-tumor effects of PDT and chemotherapeutic agents, and 
reduction in toxicity. In this review, few studies used animal models and many of them used 
subcutaneous tumor xenograft mouse models. Despite its reproducibility, the subcutaneous 
tumor xenograft mouse model presents several limitations in terms of tumor location, 
microenvironment, vasculature, and metastatic growth, which are very different from the 
human disease [46, 69]. Orthotopic models, such as direct implantation of human tumor cells 
into oral tissues and chemically-induced oral cavity SCC, may prove superior [69]. Since the 
high mortality in OSCC may be attributed to metastasis rather than the primary tumor [70], 
use of metastatic OSCC models may prove beneficial for development of novel therapies. 
Recently, Bais et al. [69], developed a metastatic model of OSCC, using human UMSCC-2 
cells. Thirty-one days after cell transplantation into the tongue, metastases were observed in 
  
sublingual tissue, the mandible, liver, lung, and bone. Another metastatic model was also 
developed using the human tongue OSC-19 cell line, which resulted in lymph node 
metastases in 28 days [71, 72]. Herein, only one study [50] evaluated the anti-metastatic 
potential of NP systems on a metastatic model of OSCC.  
In the clinical setting, clinical trials on NP systems combined with CT and/or RT are currently 
underway for treatment of recurrent and/or metastatic HNSCC [31, 32]. For instance, 
paclitaxel polymeric NPs in combination with CDDP is being explored for locally advanced 
HNSCC [31]. Among the NP systems already approved, a liposomal formulation of Dox 
(Doxil®) was used in few clinical studies in patients affected by metastatic and/or recurrent 
OSCC. While the response of the primary tumor to the treatment with Doxil was significant, 
there was no significant response of lymph node metastasis and DMs [33, 35, 36, 51].  
More advanced NP platforms that may very well be applied to OSCC therapy are present only 
in the preclinical setting and were discussed herein. For instance, third generation NP 
platforms (Fig.1) showed promising results in animal models of ovarian and breast cancer [24, 
40]. Single administration of MSVs loaded with nanoliposomes containing EphA2-specific 
siRNA resulted in a down regulation of ki67 and CD31 in an orthotopic mouse model of 
ovarian cancer [24]. Similarly, treatment with MSVs with two types of NPs (liposomes for 
siRNA delivery and PLGA-PEG NPs with DTX) reported a significant decrease of metastasis 
in mice bearing A375SM-Luc melanoma lung metastases compared to the combination of the 
two NPs without S1MPs [40].  
Moreover, an injectable NP generator (iNPG) loaded with polymeric Dox (pDox) has been 
developed and its efficacy evaluated in an orthotopic animal model of metastatic breast 
cancer [26]. pDox was obtained by conjugating Dox to poly (L-glutamic acid) through a pH-
sensitive linkage. This platform allowed for avoidance of Dox removal via drug efflux pumps. 
A significant increase of median survival time (233 d) and a decrease in Dox-induced toxicity 
was obtained in a mouse model of breast cancer lung metastasis compared to free Dox (98 d) 
and pDox NP (99 d) treatment [26].  
Nanomedicine platforms are emerging as promising therapeutic strategies for several types of 
cancer and their efficacy in OSCC is currently under investigation in the clinical setting. The 
present review highlights the current status of preclinical research in the field of nanomedicine 
for treatment of OSCC. The establishment and the use of more appropriate animal models of 
OSCC (e.g. orthotopic, metastatic models) may be suggested in order to better evaluate the 
therapeutic potential of NPs, particularly against metastasis. Furthermore, there is a need to 
assess the in vitro and in vivo efficacy of more sophisticated platforms (e.g. MSVs, iNPG) in 
OSCC. Indeed, new generation platforms may enhance the already proven benefits of NP 
based-drug delivery (e.g. overcoming chemoresistance, reducing toxicity) and concurrently 
address challenges such as metastasis. 
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Figure Legends 
 
Fig.1 Different generations of nanoparticle-based drug delivery. Summary of principal 
features of NPs of first, second, and third generation and findings from preclinical or clinical 
studies in OSCC (first and second generation).  
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